Q-omics provides the consensus-scored POF1B profile across patient tissues and cancer cell-line models. POF1B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, POF1B is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, POF1B protein abundance shows 20,050 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, KICH, and LSCC as cancer lineages where POF1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POF1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POF1B survival associations across molecular data types. POF1B RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POF1B RNA expression–survival associations across cancer types. High POF1B expression shows unfavorable associations in KIRP, UCEC and LIHC, but favorable associations in HNSC, STAD and LUSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRP as the clearest survival context for POF1B RNA expression.
This table summarizes POF1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 9. The strongest signals are observed in KICH for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for POF1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POF1B shows lower tumor expression in KICH and KIRC and higher tumor expression in LUAD, CHOL, LUSC and STAD. The KICH box plot shows higher POF1B RNA expression in normal versus tumor tissue (log2 FC = −2.507, t-test p < 0.001).
This table shows molecular features associated with POF1B in patient tissues and cancer cell lines. In patient samples, POF1B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, POF1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
